Author

Hanna Lähteenmäki

University of HelsinkiORCID 0000-0002-7914-9726Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Organism:human· 2 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Assay:CRISPR screen· 1 Approach:deep learning· 1 Approach:experimental assay· 1 Approach:statistical model· 1

Frequent Co-Authors

Aleksandr IanevskiiD· 2 shared Diogo DiasiD· 2 shared Jay KlievinkiD· 2 shared Jonas BouhlaliD· 2 shared Olli DufvaiD· 2 shared Petra Johanna NygreniD· 2 shared Satu M. MustjokiiD· 2 shared Tero A. AittokallioiD· 2 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBioinformatics

Aleksandr IanevskiORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

BioinformaticsbioRxivPreprintMay 24, 2026

Selective scoring of drug effects in multicellular co-culture systems

Diogo Dias, Aleksandr Ianevski, Jonas Bouhlal…·Tero A. Aittokallio

The paper introduces CES, a computational framework to score drug effects in multicellular co-culture systems, distinguishing between immunomodulatory effects and toxicity.

DOI 10.64898/2026.05.20.726737

humanproteomics

𝕏 PostBluesky

Cancer BiologybioRxivPreprintApr 17, 2026

Multimodal immunopharmacologic screens identify drugs rewiring the cancer-immune interface

Jonas Bouhlal, Emmi Jokinen, Petra Johanna Nygren…·Satu M. Mustjoki

The paper identifies drugs that rewiring the cancer-immune interface by enhancing NK cell function and tumor susceptibility through multimodal screening approaches.

DOI 10.64898/2026.04.13.717771

humanbulk RNA-seq

𝕏 PostBluesky